Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.

Sandor Schokker,Remco J. Molenaar,Sybren L. Meijer,Ron A. A. Mathot,Stephanie O. van der Woude,Sheila K. Krishnadath,Geert-Jan Creemers,G.A.P. Nieuwenhuijzen,Maurice J.C. van der Sangen,Laurens V. Beerepoot,Joos Heisterkamp,Maartje Los,Marije Slingerland,Annemieke Cats,Geke A.P. Hospers,Maarten F. Bijlsma,Cornelis J. A. Punt,Mark I. van Berge Henegouwen,Maarten C. C. M. Hulshof,Hanneke W. M. van Laarhoven

Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.

2018

4057Background: Around 15% of EACs are HER2+ and treatment with T is effective in metastatic EAC. Given the success of dual neoadjuvant HER2 targeted therapy with P and T in breast cancer, we perfo...

Keywords:

Trastuzumab
Pertuzumab
Cancer research
Pathology
Chemoradiotherapy
Adenocarcinoma
Medicine
esophageal adenocarcinoma
Breast cancer
Oncology
neoadjuvant chemoradiotherapy
Targeted therapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations